ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 776-800 of 1,000 matching filings.

Per page
25
Current page
32
6-K File 001-11960

ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC

Filing date
14 Dec 2020
Reporting date
14 Dec 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Dec 2020
Reporting date
01 Dec 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Dec 2020
Reporting date
01 Dec 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE

Filing date
01 Dec 2020
Reporting date
01 Dec 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE

Filing date
30 Nov 2020
Reporting date
30 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZD1222 VACCINE EFFECTIVE AGAINST COVID-19

Filing date
23 Nov 2020
Reporting date
23 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI NEW DOSING APPROVED IN THE US

Filing date
20 Nov 2020
Reporting date
20 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
13 Nov 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT

Filing date
10 Nov 2020
Reporting date
10 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE APPROVED IN THE EU FOR CLL

Filing date
09 Nov 2020
Reporting date
09 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BRILINTA APPROVED IN THE US IN STROKE

Filing date
06 Nov 2020
Reporting date
06 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN: YEAR-TO-DATE AND Q3 2020 RESULTS

Filing date
05 Nov 2020
Reporting date
05 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA APPROVED IN THE EU FOR HEART FAILURE

Filing date
05 Nov 2020
Reporting date
05 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F

Filing date
05 Nov 2020
Reporting date
05 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT

Filing date
05 Nov 2020
Reporting date
05 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Nov 2020
Reporting date
02 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES

Filing date
30 Oct 2020
Reporting date
30 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTORATE CHANGE

Filing date
29 Oct 2020
Reporting date
29 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET

Filing date
28 Oct 2020
Reporting date
28 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA

Filing date
28 Oct 2020
Reporting date
28 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW

Filing date
20 Oct 2020
Reporting date
20 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA HF RECEIVES POSITIVE CHMP OPINION

Filing date
19 Oct 2020
Reporting date
19 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION

Filing date
19 Oct 2020
Reporting date
19 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING

Filing date
13 Oct 2020
Reporting date
13 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE

Filing date
02 Oct 2020
Reporting date
02 Oct 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .